Sagimet Biosciences Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
30.7M
on 2024-11-08, from 30.4M on 2024-05-10 10-Q ↗
a raise that quarter, at its price
Newest
S-3 of 2024-08-15. Not read yet. S-3 ↗
$75.0M
Leerink Partners, agreement of 2025-08-14. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Warrants
The 10-Q filed 2026-08-11 is not read yet.
Cash
23 quarters
$240.1M on 2026-06-30 ÷ $10.4M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-09-30 | Public offering incl. 2.75M pre-funded | 11,500,020 | $10.00 | $115.0M | 424B5 ↗ |
| 2026-04-27 | Public offering | 29,166,700 | $6.00 | $175.0M | 424B5 ↗ |